Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1993-06-11
1995-09-12
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514492, 514908, 536 41, 536 2855, 544313, 556136, 556137, A61K 3170, A61K 3128, A61K 31505
Patent
active
054496632
ABSTRACT:
Anti-cancer compositions containing chiral monosaccharides and methods of their use are disclosed herein. The compositions, exhibiting cytostatic and cytotoxic properties with regard to neoplastic cells are formulated using the L-isomeric form of monosaccharides. A preferred embodiment of the invention employs the L-isomeric form of glucose with a pharmaceutically acceptable carrier. The compositions may be used alone or as an adjunct to other forms of cancer therapy. They are useful in combination with all major forms of cancer therapy including surgery, biological and chemical therapies, radiation therapy, and hyperthermia. In addition to increasing the mortality rate of neoplastic cells, these compositions can reduce the metastatic potential of the tumor, and slow the growth of the malignancy.
REFERENCES:
patent: 4262032 (1981-04-01), Levin et al.
patent: 4451569 (1984-05-01), Kobayashi et al.
patent: 4581447 (1986-04-01), Arena
patent: 4863740 (1989-09-01), Kissel et al.
patent: 4904467 (1990-02-01), Schwulera
patent: 5059421 (1991-10-01), Loughrey et al.
patent: 5061492 (1991-10-01), Okada et al.
patent: 5114919 (1992-05-01), Baldwin et al.
patent: 5166193 (1992-11-01), Levin et al.
patent: 5219573 (1993-06-01), Tarka, Jr. et al.
C. Streffer and F. Steinberg, Effects on Glucose and Oxygen Metalbolism as Well as Cell Proliferation after Treatment of Tumors with X-Rays, Heat and Sensitizers, Proc. 6th Intnl. Cong. on Hypathermic Oncology vol. 1 Dietzel-F, Basic Principles in Hyperthermic Tumor Therapy, Recent-Results-Cancer-Res, vol. 86, iss. 8 (1983): 177-90.
Satomura-T, et al., Tumor Suppressing Effect of Systemic Hyperthermia with 2350 MH.sub.2 Microwaves Combined with 5-Fluorouracil in Mice, Gan-To-Kagaku-Ryoho, vol. 10, iss. 11 (1983 Nov): 2292-300.
Gillette-E-L, Clinical Use of Thermal Enhancement and Therapeutic Gain for Hyperthermia Combined with Radiation or Drugs, Cancer-Res, vol. 44, iss. 10 Suppl (1984 Oct): 4836s-4841s.
Lange-J., et al, The Effect of Whole Body Hyperthermia on 5-Fluorouracil Pharmacokinetics in Vivo and Clonogenicity of Mammalian Colon Cancer Cells, Anticancer-Res, vol. 4, iss. 1-2 (1984 Jan.-Apr.): 27-31.
B. S. Dwarkanath, PhD., et al, Energy Linked Modifications of the Radiation Response in a Human Cerebral Glioma Cell Line, 17 May 1989.
Thomas Volk, et al, Effect of Glucose-Mediated pH Reduction and Cyclophosphamide on Oxygenation of Transplanted Rat Tumors, 31 Jul. 1992.
J. H. Kim, et al, Hypoxic Cell Radiosensitization by Moderate Hyperthermia and Glucose Deprivation, Radiation Research 93, 416-420 (1983).
Dancis-J., et al, Trnsfer and Metabolism of Dideoxyinosine by the Perfused Human Placenta, Journal of Acquired Immune Deficiency Syndromes, vol. 6, iss. 1 (1993 Jan): 2-6.
Dwarkanath et al., "Energy Linked Modification . . . Glioma Cell Line", Int'l J Rad. Onc. Bio. Physics, 1984 (1989?), 17:5, pp. 1033-1040.
Johnston et al. J. Med. Chem. 22(5), pp. 597-599, (1979).
Suffrin et al. J. Med. Chem. 23(2), pp. 143-149, (1980).
Florent et al. J. Antibiotics 42(12), pp. 1823-1830, (1989).
Tan et al. J. Singapore Natl. Acad. Sci. 4(3), pp. 106-109, (1975).
Seltzer et al. Growth 33(4), pp. 353-359, (1969).
May et al. J. Med. Chem 22(8), pp. 971-976, (1979).
Lee Howard C.
Robinson Douglas W.
LandOfFree
Antineoplastic compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antineoplastic compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antineoplastic compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-405354